about
Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD StudyPredictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.Huntington disease: natural history, biomarkers and prospects for therapeutics.Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.What is the impact of education on Huntington's disease?Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.Tapping linked to function and structure in premanifest and symptomatic Huntington diseaseMagnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study.Deficits in tongue motor control are linked to microstructural brain damage in multiple sclerosis: a pilot studyQuantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study.Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical PerformanceGrasping multiple sclerosis: do quantitative motor assessments provide a link between structure and function?Progression of motor subtypes in Huntington's disease: a 6-year follow-up study.Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline.Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.Technology in Parkinson's disease: Challenges and opportunities.Corpus callosal atrophy in premanifest and early Huntington's disease.A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up.Wearable Sensors in Huntington Disease: A Pilot Study.Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.Grasping premanifest Huntington's disease - shaping new endpoints for new trials.Behavioral phenotyping of minipigs transgenic for the Huntington gene.Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease.Behavioral testing of minipigs transgenic for the Huntington gene-A three-year observational study.Remission of progressive multifocal leucoencephalopathy in SLE after treatment with cidofovir: a 4 year follow up.Coordination of fingertip forces during precision grasping in multiple system atrophy.Physical therapy in Huntington's disease--toward objective assessments?Creatine supplementation lowers brain glutamate levels in Huntington's disease.Does chromatin modulation provide the first wet biomarker for Huntington's disease?An important step towards translation of stem cell therapies in clinical applications for neurodegenerative diseases and beyond?The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease.Neuroimaging of a minipig model of Huntington's disease: Feasibility of volumetric, diffusion-weighted and spectroscopic assessments.One-year safety and tolerability profile of pridopidine in patients with Huntington disease.Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease.The pridopidine paradox in Huntington's disease.Huntington's disease: N-methyl-D-aspartate receptor coagonist glycine is increased in platelets.Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease.
P50
Q28393234-F759A380-2545-4032-A81D-8FBAAD2BB007Q30624346-910ED6BA-D1E1-4CC4-8557-C24C5730132EQ30774172-B4647660-4DFB-4BB7-9DB4-9CBFD3AACE6CQ33489152-D2CD132A-8DF6-4D95-8E33-526B6A30BDD3Q34089875-88F7B2EE-CD7D-4E93-8AB7-73E4EC4502F7Q34172955-54DAECC1-7C43-4D51-B6E2-4B831BFDDC5BQ34231219-7DF9EB22-9E69-43F7-A1C9-1DFEF9682C56Q34455567-203B1493-8235-4F12-A06D-2EB33A38EFEFQ34551626-2B50D42F-9F06-4B64-A935-F0D3FBC90EFEQ35526097-8C5044CE-EF88-44AF-99F5-C653D5D82BAFQ35801089-8B616C8D-7A2D-431E-A8D7-2C148E98C61FQ35877852-3226AB96-7626-4F29-849B-DBD709C6A5F2Q35906778-C2B6B8B5-F04B-4DDC-AF33-23178D30159BQ36592666-AE1DDC95-AED5-456C-83C0-3284FAADC713Q37284637-165008B2-B4F0-49B2-8B70-7347F5953A35Q38106927-BF39B021-64B4-40CC-8156-8C85E2EC0B19Q38248689-CFCFBFA6-17F6-47EE-A162-8B9EB80F731AQ38820246-EC0FE32B-AD68-47BF-ABCB-CE9F3064A328Q38956033-84263D23-3DAC-4AC3-B59E-C7F741993ED2Q39037892-FFAA7246-7626-4DB5-9A15-3AC5B7B09B71Q39564387-1C548D7D-FE45-42FE-8587-E1A322C25CD9Q39657388-62EF7658-A014-485A-B985-6541E76529A8Q39809906-6E43AAA2-A189-4A30-80D3-3900AA8DAF22Q39840720-196665BA-074C-40F0-985C-FE85CE341B4BQ40187877-F5D58DFD-7B37-472C-9119-45C714860DF3Q41821958-049EAC1D-5321-4BC6-9746-E2A704B297DBQ42708331-B810B3B8-1B91-448B-992F-370A5EF8BCE1Q43067503-503AD4E3-ECA3-4B09-9DC7-CC9E83F42190Q44505622-77719F67-4A13-4A77-B3C1-B8E4C8AA025DQ44739587-002508FD-48F7-4754-99D6-A128E27561DAQ45239341-64D4876A-1C24-4A63-97AB-C2F4BEAD8D9BQ45288713-5F4B92C0-30B3-47FF-8416-9362BD6BE86DQ45290763-E841B9E1-9577-4EF0-98FE-5B5D1D68687CQ45291023-B60D3CF0-9748-4CE3-A0A0-B90A83113180Q45291870-4534C2F7-8F5C-49DC-8486-E73EAFE02E5EQ45292164-CDB06730-E4B0-4393-99C3-896603E30015Q45292387-13D5624D-0C89-44F5-AFF4-3D0A5CD23FE5Q45294030-26DA933F-6ABA-4F91-86ED-CEB2A1826D57Q45294356-70DD09C5-F871-438B-8332-0B265F807C6DQ45298485-DEB1F7A6-7335-4D57-8BDD-A77C3F0ACBC2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ralf Reilmann
@ast
Ralf Reilmann
@de
Ralf Reilmann
@en
Ralf Reilmann
@es
Ralf Reilmann
@nl
type
label
Ralf Reilmann
@ast
Ralf Reilmann
@de
Ralf Reilmann
@en
Ralf Reilmann
@es
Ralf Reilmann
@nl
altLabel
R Reilmann
@en
prefLabel
Ralf Reilmann
@ast
Ralf Reilmann
@de
Ralf Reilmann
@en
Ralf Reilmann
@es
Ralf Reilmann
@nl
P214
P227
P101
P106
P21
P213
0000 0003 6941 9945
P214
P227
P31
P496
0000-0002-5904-9517
P569
1967-01-01T00:00:00Z
P7859
viaf-238548533